Dyne Therapeutics Inc
DYN
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.9B
Close$
$6.80
73.8% downside
Current Fair Value
73.8% downsideOvervalued by 73.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.90 Billion |
|---|---|
| Enterprise Value | $4.25 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.47 |
| Beta | 1.06 |
| Outstanding Shares | 165,451,388 |
Return
| Return on Equity | -73.97% |
|---|---|
| Return on Assets | -52.25% |
| Return on Invested Capital | -56.27% |
Valuation & Multiples
| P/E Ratio | -7.88 |
|---|---|
| PEG | -12.91 |
| Price to Sales | - |
| Price to Book Ratio | 6.49 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -8.24 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$-0.75
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 624.74% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 16.03%▼ 97.79% |
|---|---|
| Total Invested | $587.40M▼ 82.74% |
| Investors Holding | 76▼ 159.00% |
ESG Score
No data
About Dyne Therapeutics Inc
47 employeesDyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in the United States.